Abstract 239P
Background
With the induction of molecular targeted therapy and immune checkpoint inhibitors, treatment strategies for systemic treatment of metastatic clear cell renal cell carcinoma (mCCRCC) have been changed with improved survival. However, for those patients diagnosed as metastatic non-clear cell renal cell carcinoma (mNCRCC), systemic therapy designed and approved for mCCRCC have been used because no validated systemic therapy exists. This retrospective study aimed to identify prognostic factors for patients with mNCRCC treated with systemic therapy.
Methods
A total of 270 patients were reviewed. Among them, 41 patients who pathologically diagnosed as mNCRCC and received systemic therapy were retrospectively analyzed. Clinical and pathological data were retrieved and analyzed retrospectively. The progression free survival (PFS) and overall survival (OS) between mNCRCC and mCCRCC patients were compared. The OS for patients with mNCRCC was further investigated with univariate and multivariate Cox’s proportional hazards regression models.
Results
After a median follow-up of 31.3 months after first-line treatment initiation, the median PFS was 3.3 and 20.8 months for mNCRCC and mCCRCC, respectively (p<0.0001). The median OS was 19.6 and 54.4 months for mNCRCC and mCCRCC, respectively (p<0.0001). For patients with mNCRCC, univariate Cox proportional hazards model analyses revealed that the duration of first-line treatment (p<0.0001), the time to first-line treatment within 1 year (p=0.0201), high corrected serum calcium (p=0.0006), high neutrophil count (p=0.0003), and the baseline CRP level (p=0.0034) were significantly correlated with shorter OS, respectively. Furthermore, a multivariate analysis revealed the duration of first-line treatment (Hazard ratio (HR): 0.89, 95% CI: 0.81-0.97, p=0.007), the high corrected serum calcium (HR: 4.04, 95% CI: 1.58-10.37, p=0.004), and the baseline CRP level (HR: 1.15, 95% CI: 1.05-1.25, p=0.002) were independent predictors for OS in mNCRCC patients.
Conclusions
Patients with mNCCC resulted in shorter PFS and OS. Elevated baseline C-reactive protein, a prognostic factor for mCCRCC, was also correlated with shorter OS in mNCRCC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
101P - The coexistence of TP53 gain-of-function mutation and hypermethylation as a poor prognostic factor in BRAF wild-type metastatic colorectal cancer
Presenter: Kota Ouchi
Session: Poster Display
Resources:
Abstract
102P - Enhancing colorectal cancer prevention in high-risk populations through faecal immunochemical test surveillance
Presenter: Li Xie
Session: Poster Display
Resources:
Abstract
103P - Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort A
Presenter: Junwei Wu
Session: Poster Display
Resources:
Abstract
104P - The value of functional MR-imaging signature model for early prediction of chemotherapy response and its guidance for regimen adjustment to improve efficacy
Presenter: Wenhua Li
Session: Poster Display
Resources:
Abstract
105P - A single-arm, phase II, multicenter study of iparomlimab (QL1604) in patients (pts) with unresectable/metastatic deficient mismatch repair (dMMR)/microsatellite instability high (MSI-H) solid tumors
Presenter: Weijian Guo
Session: Poster Display
Resources:
Abstract
106P - Efficacy and safety of IBI351 (GFH925) monotherapy in metastatic colorectal cancer harboring KRASG12C mutation: Updated results from a pooled analysis of two phase I studies
Presenter: Ying Yuan
Session: Poster Display
Resources:
Abstract
107P - Tumor-stromal ratio in a new age fibroblast activated protein PET imaging as a biomarker for prediction of response to neoadjuvant chemoradiotherapy in carcinoma rectum
Presenter: swetha Suresh
Session: Poster Display
Resources:
Abstract
108P - Detection of HER2 overexpression in colorectal cancer: Comparison of a HANDLE classic NGS panel with standard IHC/FISH
Presenter: Lijuan Luan
Session: Poster Display
Resources:
Abstract
109P - Early onset metastatic colorectal cancer: Clinical-prognostic characteristics and correlation to molecular status
Presenter: Andrea Pretta
Session: Poster Display
Resources:
Abstract
110P - The correlation between multi-dimensional characteristics of circulating tumor cells (CTC) and treatment response in patients with initially unresectable metastatic colorectal cancer
Presenter: Yu Liu
Session: Poster Display
Resources:
Abstract